Spontaneous Pneumomediastinum Associated with Semaglutide Therapy: A Case Report.

IF 0.7 Q4 GASTROENTEROLOGY & HEPATOLOGY

Case Reports in Gastroenterology Pub Date : 2026-04-02 eCollection Date: 2026-01-01 DOI:10.1159/000551669

Johanna Diebold, Christoph Gubler, Fritz Ruprecht Murray

{"title":"Spontaneous Pneumomediastinum Associated with Semaglutide Therapy: A Case Report.","authors":"Johanna Diebold, Christoph Gubler, Fritz Ruprecht Murray","doi":"10.1159/000551669","DOIUrl":null,"url":null,"abstract":"Introduction: The seemingly harmless side effects of semaglutide, such as vomiting, may rarely lead to serious complications. This case is unique in highlighting spontaneous pneumomediastinum (SPM) as a potential consequence of unsupervised semaglutide use, adding new insight to the literature on the safety profile of weight-loss medications.Case presentation: We report the case of a 26-year-old woman who developed SPM shortly after the self-administered use of semaglutide purchased online for weight loss. The patient presented with vomiting, chest and neck pain, and progressive facial swelling. Imaging revealed extensive pneumomediastinum and cervicothoracic emphysema. Oesophago-gastro-duodenoscopy was performed to rule out oesophageal perforation and showed no abnormalities. The patient was managed conservatively with spontaneous recovery.Conclusion: This case highlights the importance of distinguishing SPM from life-threatening conditions such as Boerhaave's syndrome and raises concerns regarding the unsupervised use of injectable weight-loss medications, emphasizing the need for patient education and careful monitoring.","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"20 1","pages":"149-156"},"PeriodicalIF":0.7000,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263006/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000551669","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The seemingly harmless side effects of semaglutide, such as vomiting, may rarely lead to serious complications. This case is unique in highlighting spontaneous pneumomediastinum (SPM) as a potential consequence of unsupervised semaglutide use, adding new insight to the literature on the safety profile of weight-loss medications.

Case presentation: We report the case of a 26-year-old woman who developed SPM shortly after the self-administered use of semaglutide purchased online for weight loss. The patient presented with vomiting, chest and neck pain, and progressive facial swelling. Imaging revealed extensive pneumomediastinum and cervicothoracic emphysema. Oesophago-gastro-duodenoscopy was performed to rule out oesophageal perforation and showed no abnormalities. The patient was managed conservatively with spontaneous recovery.

Conclusion: This case highlights the importance of distinguishing SPM from life-threatening conditions such as Boerhaave's syndrome and raises concerns regarding the unsupervised use of injectable weight-loss medications, emphasizing the need for patient education and careful monitoring.

查看原文本刊更多论文

自发性纵隔气肿与西马鲁肽治疗相关：1例报告。

semaglutide看似无害的副作用，如呕吐，很少会导致严重的并发症。该病例突出了自发性纵隔气肿（SPM）作为无监督使用西马鲁肽的潜在后果，为减肥药的安全性文献增加了新的见解。病例介绍：我们报告一例26岁的妇女谁发展SPM后不久自行使用网上购买的西马鲁肽减肥。患者表现为呕吐、胸颈疼痛和进行性面部肿胀。影像显示广泛的纵隔气肿和颈胸肺气肿。行食管-胃-十二指肠镜检查，排除食管穿孔，未见异常。患者接受保守治疗，自行恢复。结论：该病例强调了将SPM与危及生命的疾病（如Boerhaave综合征）区分开来的重要性，并引起了对无监督使用注射减肥药的关注，强调了对患者进行教育和仔细监测的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊